Taysha Gene Therapies Inc (NASDAQ: TSHA) kicked off on Tuesday, up 2.61% from the previous trading day, before settling in for the closing price of $1.53. Over the past 52 weeks, TSHA has traded in a range of $1.19-$4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 129.39% over the last five years. While this was happening, its average annual earnings per share was recorded 61.44%. With a float of $153.61 million, this company’s outstanding shares have now reached $204.94 million.
The firm has a total of 52 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.31%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 61.44% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Take a look at Taysha Gene Therapies Inc’s (TSHA) current performance indicators. Last quarter, stock had a quick ratio of 5.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Analysing the last 5-days average volume posted by the [Taysha Gene Therapies Inc, TSHA], we can find that recorded value of 2.03 million was lower than the volume posted last year of 2.19 million. As of the previous 9 days, the stock’s Stochastic %D was 53.76%. Additionally, its Average True Range was 0.13.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 17.92%, which indicates a significant decrease from 42.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.35% in the past 14 days, which was lower than the 102.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0003, while its 200-day Moving Average is $2.2819. Now, the first resistance to watch is $1.6533. This is followed by the second major resistance level at $1.7367. The third major resistance level sits at $1.8133. If the price goes on to break the first support level at $1.4933, it is likely to go to the next support level at $1.4167. Should the price break the second support level, the third support level stands at $1.3333.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
The company with the Market Capitalisation of 321.76 million has total of 204,943K Shares Outstanding. Its annual sales at the moment are 15,450 K in contrast with the sum of -111,570 K annual income. Company’s last quarter sales were recorded 1,790 K and last quarter income was -25,520 K.
